Skip to main content

UTI Suppressive and Prophylactic Therapy

Recurrent urinary tract infection (rUTI) — defined as ≥2 symptomatic, culture-confirmed UTIs in 6 months or ≥3 in 12 months — is one of the most common chronic problems in functional urology and urogynecology. The overarching goal of prophylaxis is to improve quality of life while minimizing antimicrobial exposure.[1][2] The AUA/CUA/SUFU 2025 guideline supports shared selection of antibiotic and non-antibiotic prevention; methenamine is now a conditional option for eligible women with rUTI. It does not require every patient to complete a fixed sequence before antibiotic prophylaxis.[21]

Treat an active symptomatic infection before beginning methenamine prophylaxis. In an otherwise uncomplicated, nonpregnant woman whose symptoms resolve, do not require a routine negative test-of-cure culture. Reassess and culture persistent or recurrent symptoms.[21][22]

For adjacent topics, see UTI treatment antibiotics, Non-antibiotic UTI prevention, and Recurrent UTI (clinical).

Prevention framework​

Use this as a menu for individualized prevention, not a mandatory treatment ladder. Consider non-antibiotic options and stewardship while matching therapy to recurrence pattern, eligibility, tolerability, and preferences.[4][5][6][21]

StrategyInterventions
Behavioral / non-pharmacologicConsider increased water for low-volume drinkers; review spermicide use and relevant voiding/bowel dysfunction
Non-antibiotic prophylaxisVaginal estrogen (first-line in postmenopausal women), methenamine hippurate, cranberry proanthocyanidins
Self-start / symptomatic therapyPre-prescribed treatment course for patients who can reliably self-diagnose
Antibiotic prophylaxisPost-coital single dose or continuous low dose, selected by recurrence pattern
Immunoprophylaxis (where available)OM-89, MV140, Urovac — not FDA-approved in the US

Non-antibiotic prophylaxis​

Vaginal estrogen — first-line in postmenopausal women​

Vaginal estrogen restores Lactobacillus colonization, lowers vaginal pH, and reduces uropathogen colonization — the mechanistic basis of GSM-driven rUTI. Available as vaginal cream, tablets / inserts (e.g., estradiol 10 µg tablets), and the estradiol ring. An older meta-analysis found an imprecise effect (RR 0.42; 95% CI 0.16–1.10); current AUA guidance recommends vaginal estrogen in eligible peri- and postmenopausal women. Use the estrogen hub for contemporary evidence and product-specific safety.[7]

Systemic estrogen should not be used for UTI prevention.[4] See GSM for the full treatment framework.

Methenamine hippurate — AUA-endorsed alternative to daily antibiotics​

Methenamine is an option for women seeking to reduce daily antibiotic exposure (AUA 2025 Conditional Recommendation, Grade C). Do not routinely pair it with vitamin C. Use the methenamine prescribing section for the regimen, urine-pH/label distinction, and contraindication check.[21]

ALTAR trial (Harding 2022, BMJ, multicenter open-label non-inferiority RCT, n = 240 women with rUTI):[8][9]

  • Methenamine hippurate 1 g BID vs daily low-dose antibiotics (nitrofurantoin 50–100 mg, trimethoprim 100 mg, or cefalexin 250 mg) over 12 months
  • Incidence 1.38 vs 0.89 episodes/person-year — absolute difference 0.49, within the predefined non-inferiority margin of 1 UTI/person-year
  • Antibiotic resistance in E. coli from perineal swabs was significantly higher in the antibiotic arm (72% vs 56%; p = 0.05) during treatment
  • Non-inferiority used a one-UTI/person-year margin; it does not establish identical recurrence rates. Resistance findings depended on timing: post-treatment multidrug resistance was numerically higher with methenamine (20% vs 5%; p = 0.06).

ImpresU trial (Heltveit-Olsen 2025, CMI, triple-blind placebo-controlled phase IV RCT, 289 recruited / 281 analyzed women ≥70 y):[10]

  • 6-month course: methenamine reduced antibiotic-treated UTIs by ~25% (IRR 0.75; 95% CI 0.57–1.0; p = 0.049)
  • Rebound effect after discontinuation: UTI incidence rose in the methenamine group (IRR 1.7; p < 0.05) — suggesting prophylactic benefit is confined to the treatment period

Emerging caveat: the frmRAB operon can confer formaldehyde resistance in some E. coli strains; the clinical impact is under investigation.[11]

Cranberry products​

The AUA 2025 guideline recommends offering cranberry as an option (Moderate / Grade B). Declared PAC content helps product selection, but a ≥36 mg threshold does not guarantee efficacy. WikiGuidelines also discusses selected populations.[6] Meta-analysis: RR 0.53 (95% CI 0.33–0.83) for recurrence.[7] Evidence is insufficient in older adults, patients with bladder-emptying problems, and pregnancy.[6]

D-mannose — negative in the largest rigorous RCT​

D-mannose binds type-1 fimbriae and theoretically blocks E. coli adherence to the urothelium. Small trials suggested benefit, but the MERIT RCT (Hayward 2024, JAMA Intern Med, n = 598 women in primary care with rUTI) was negative: 51.0% of D-mannose patients vs 55.7% of placebo patients experienced a medically attended UTI over 6 months.[12] The authors explicitly concluded D-mannose should not be recommended to prevent future UTIs in this population.

Increased water intake​

One RCT showed benefit from an additional 1.5 L of water daily in healthy premenopausal women who initially drank less than 1.5 L/day.[6] Offer increased intake to low-volume drinkers when appropriate; do not prescribe the same extra volume to every patient or override fluid restrictions.

Probiotics​

Evidence for vaginal or oral Lactobacillus products is heterogeneous across strains, routes, and populations — uncertain preventive benefit; a generic probiotic is not an established adjunct to vaginal estrogen.[5][6]

Antibiotic prophylaxis​

For women meeting rUTI criteria, antibiotic prophylaxis may be chosen after discussing benefits, harms, and alternatives; prior failure of every non-antibiotic option is not an AUA requirement.[21] A systematic review and meta-analysis of 11 placebo-controlled trials (Jent 2022) showed antibiotic prophylaxis reduces UTI risk by 85% (RR 0.15; 95% CI 0.08–0.29), with no significant efficacy difference among nitrofurantoin, TMP-SMX, and norfloxacin in head-to-head comparisons.[13]

Continuous prophylaxis​

An initial time-limited course with planned reassessment is appropriate. Most trial evidence covers 6–12 months; continuing prophylaxis for years is not established by that evidence.[21]

AgentTypical continuous dosePractical notes
Nitrofurantoin50–100 mg nightlyUse only when organism and patient are suitable; monitor pulmonary, hepatic and neuropathic toxicity. Modern guidance often uses CrCl 30, while US labeling remains more restrictive; see treatment hub[1][2]
TMP-SMX40/200 mg nightly or 3×/weekUse prior culture susceptibility; check hyperkalemia, renal function and interactions. The 20% threshold concerns empirical acute treatment, not a rule overriding an individual susceptible isolate[1][2]
Trimethoprim (monotherapy)100 mg nightlyMay avoid the sulfonamide component, but trimethoprim-related hyperkalemia / renal effects remain[3]
Cephalexin125–250 mg nightlyALTAR comparator; reasonable β-lactam option[8]
Fosfomycin3 g PO every 10 daysEmerging; limited prophylaxis trial data

Post-coital prophylaxis​

For women whose UTIs are temporally related to intercourse, a single dose taken before or after intercourse is an effective option that may reduce total exposure; comparative studies have not shown a significant difference from continuous dosing.[2][3][13]

AgentPost-coital dose
TMP-SMX40/200 mg or 80/400 mg single dose
Nitrofurantoin50–100 mg single dose
Cephalexin250 mg single dose

Self-start (patient-initiated) therapy​

Selected reliable patients may use a pre-agreed short treatment course while awaiting urine-culture results; obtain a specimen before treatment when feasible and adjust to results. Eligibility is not defined by a ≤2-UTI/year cutoff. Include instructions for fever, flank pain, pregnancy, persistent symptoms and other reasons for reassessment.[2][3]

Immunoprophylaxis​

These products are not FDA-approved in the US. Current EAU guidance limits immunomodulatory prophylaxis to a well-regulated clinical trial (Weak); older regional recommendations should be read in that context.[24]

  • OM-89 (Uro-Vaxom) — oral immunostimulant containing lyophilized E. coli lysate. Meta-analysis of 4 trials (n = 891) showed RR 0.61 (95% CI 0.48–0.78) for recurrence; good safety profile. Grade A recommendation in the Latin American rUTI consensus.[7][14]
  • MV140 (Uromune) — sublingual polybacterial preparation. A frail-elderly cohort is observational. A completed 240-woman placebo-controlled RCT found 56–58% UTI-free with MV140 versus 25% with placebo during the nine-month efficacy period; it was industry-funded and does not establish efficacy in every complex population.[23][15]
  • Urovac — vaginal mucosal vaccine; RR 0.75 (95% CI 0.63–0.89) with booster-dependent efficacy.[16]
  • Systematic review (Aziminia 2019, 10 RCTs, n = 1,537): vaccines reduced rUTI vs placebo (RR 0.74; 95% CI 0.67–0.81), low-quality evidence with substantial heterogeneity.[16]

Special populations​

Pregnancy​

After treating a UTI in pregnancy in a woman with prior rUTI, ACOG 2023 states clinicians may consider initiating antimicrobial suppression for the remainder of pregnancy using a once-daily low dose of a susceptible agent; continuous or post-coital regimens are both acceptable. Evidence is limited.[17]

Kidney transplant recipients​

TMP-SMX used for Pneumocystis prophylaxis after transplantation can also reduce UTI; coordinate any change with the transplant team.[19] Do not layer methenamine onto TMP-SMX: the US methenamine label excludes concurrent sulfonamides and renal insufficiency. See the methenamine safety section.[22] IDSA recommends against routine screening/treatment of asymptomatic bacteriuria more than one month after renal transplantation; evidence is insufficient within the first month.[18]

Spinal cord injury / neurogenic bladder​

Reassess emptying, bladder pressures, stones and catheter practice. AUA/SUFU advises against daily prophylaxis with an indwelling catheter or CIC without recurrent UTI. For CIC users with recurrent UTI, oral prophylaxis may be offered after discussing antimicrobial resistance (Conditional / Grade C); bladder instillation is an Expert Opinion option.[20][25]

The AnTIC RCT randomized 404 adults using intermittent self-catheterization (361 in the primary analysis): prophylaxis reduced antibiotic-treated symptomatic UTIs from 2.6 to 1.3/person-year (IRR 0.52), but resistant urinary isolates increased. This mixed catheterizing population supports individualized benefit–harm decisions, not prophylaxis for all SCI or catheterized patients.[26]

Post-reconstruction / diversion patients​

  • Continent cutaneous diversions, neobladder, augmentation cystoplasty — colonization is expected; treat only symptomatic infection
  • Recurrent symptomatic UTI in diversion patients should trigger evaluation for stones, retained mucus, incomplete emptying, or obstructed efferent limb before escalating antibiotic strategy
  • IPP and AUS patients need syndrome- and culture-directed UTI treatment; device presence alone does not mandate broader antibiotics or suppression. Assess suspected device infection separately

Monitoring and duration​

  • Agree a time-limited course and review date; studies commonly cover 6–12 months.[2][3]
  • Do not present multi-year prophylaxis as proven safe or resistance-free; continued use requires individualized reassessment.[21]
  • Benefit may diminish after stopping; ImpresU found more antibiotic-treated episodes after discontinuation, which does not by itself justify indefinite therapy.[6][10]
  • Periodic reassessment of strategy — including de-escalation to non-antibiotic prophylaxis or symptomatic self-start therapy — is appropriate.[2]
  • Screen for emerging nitrofurantoin pulmonary / hepatic toxicity in patients on long-term suppression; audit TMP-SMX recipients for hyperkalemia and renal function.

Evidence Summary​

StrategyEvidence levelKey trial / guidelineNotes
rUTI guideline frameworkRecommendations vary by interventionAUA/CUA/SUFU 2025[21]Shared selection; methenamine Conditional / Grade C
Methenamine non-inferiority to antibioticsLevel 1ALTAR 2022 BMJ[8][9]; ImpresU 2025 CMI[10]Non-inferior; placebo-superior in older women
Antibiotic prophylaxis efficacyLevel 1Jent 2022 meta (11 RCTs)[13]85% reduction vs placebo
Vaginal estrogen in peri/postmenopausal rUTIAUA Moderate / Grade BAUA 2025[21]Recommend when eligible
CranberryAUA Moderate / Grade BAUA 2025[21]Offer as an option; product variability
D-mannoseLevel 1MERIT RCT 2024[12]Negative in largest primary-care RCT
Hydration + 1.5 L/dayLevel 2WikiGuidelines 2024[6]Reasonable low-risk measure
Immunoprophylaxis (OM-89, MV140, Urovac)Level 2Aziminia 2019 SR[16]RR 0.74; low-quality evidence; not FDA-approved

Clinical Positioning​

  • Discuss eligible non-antibiotic options early and select a prevention strategy together; use the prescribing hub for the methenamine regimen and safety checks.[6][21]
  • Methenamine met ALTAR's prespecified non-inferiority margin in women with rUTI. Check population applicability and contraindications; this is not a blanket recommendation for catheterized, neurogenic, or renal-insufficient patients.[8][9][22]
  • D-mannose evidence no longer supports routine use. The 2024 JAMA Intern Med MERIT trial is the largest and most rigorous data point and is negative.[12]
  • For coitus-related rUTI, post-coital prophylaxis may reduce antibiotic exposure while preventing recurrence.[13]
  • Self-start therapy is an option for selected reliable patients with a culture/follow-up plan.[2]
  • Set a review date. Reassess prevention benefit, toxicity, and recurrent episodes; benefit may diminish after treatment ends and evidence does not establish multi-year safety.[10][21]
  • Nitrofurantoin and TMP-SMX are the workhorses; fluoroquinolones are not recommended for routine rUTI prophylaxis given their harms.[13]
  • Do not treat asymptomatic bacteriuria in transplant, SCI, diversion, or catheter patients outside the IDSA 2019 exceptions — it does not prevent symptomatic UTI and accelerates resistance.[18][20]
  • In neurogenic patients, investigate correctable causes and match prophylaxis to the catheter/recurrence setting. CIC with recurrent UTI differs from asymptomatic bacteriuria or an indwelling catheter.[20]
  • Immunoprophylaxis remains investigational in the US. Review current jurisdictional availability and trial evidence rather than applying older regional grades universally.[14][15][16]

See Also​

References​

1. Anger JT, Bixler BR, Holmes RS, et al. "Updates to recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline." J Urol. 2022;208(3):536–541. doi:10.1097/JU.0000000000002860

2. Hooton TM. "Uncomplicated urinary tract infection." N Engl J Med. 2012;366(11):1028–1037. doi:10.1056/NEJMcp1104429

3. Fihn SD. "Acute uncomplicated urinary tract infection in women." N Engl J Med. 2003;349(3):259–266. doi:10.1056/NEJMcp030027

4. Siddiqui NY, Bradley MS. "Updates in clinical management of recurrent urinary tract infections." Obstet Gynecol. 2025. doi:10.1097/AOG.0000000000006060

5. Smith AL, Brown J, Wyman JF, et al. "Treatment and prevention of recurrent lower urinary tract infections in women: a rapid review with practice recommendations." J Urol. 2018;200(6):1174–1191. doi:10.1016/j.juro.2018.04.088

6. Nelson Z, Aslan AT, Beahm NP, et al. "Guidelines for the prevention, diagnosis, and management of urinary tract infections in pediatrics and adults: a WikiGuidelines group consensus statement." JAMA Netw Open. 2024;7(11):e2444495. doi:10.1001/jamanetworkopen.2024.44495

7. Beerepoot MA, Geerlings SE, van Haarst EP, van Charante NM, ter Riet G. "Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials." J Urol. 2013;190(6):1981–1989. doi:10.1016/j.juro.2013.04.142

8. Harding C, Mossop H, Homer T, et al. "Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open-label, randomised, non-inferiority trial (ALTAR)." BMJ. 2022;376:e068229. doi:10.1136/bmj-2021-0068229

9. Harding C, Chadwick T, Homer T, et al. "Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT." Health Technol Assess. 2022;26(23):1–172. doi:10.3310/QOIZ6538

10. Heltveit-Olsen SR, Arnljots ES, Sundvall PD, et al. "Methenamine hippurate as prophylaxis for recurrent urinary tract infections in older women — a triple-blind, randomised, placebo-controlled, phase IV trial (ImpresU)." Clin Microbiol Infect. 2025. doi:10.1016/j.cmi.2025.07.006

11. Hodgkinson NC, Al-Rubaye T, Reed TCP, et al. "Implications for methenamine hippurate use in recurrent urinary tract infection management: formaldehyde resistance and altered urinary composition." PLoS Pathog. 2026;22(3):e1014081. doi:10.1371/journal.ppat.1014081

12. Hayward G, Mort S, Hay AD, et al. "D-mannose for prevention of recurrent urinary tract infection among women: a randomized clinical trial (MERIT)." JAMA Intern Med. 2024;184(6):619–628. doi:10.1001/jamainternmed.2024.0264

13. Jent P, Berger J, Kuhn A, et al. "Antibiotics for preventing recurrent urinary tract infection: systematic review and meta-analysis." Open Forum Infect Dis. 2022;9(7):ofac327. doi:10.1093/ofid/ofac327

14. Haddad JM, Ubertazzi E, Cabrera OS, et al. "Latin American consensus on uncomplicated recurrent urinary tract infection — 2018." Int Urogynecol J. 2020;31(1):35–44. doi:10.1007/s00192-019-04079-5

15. Lorenzo-Gómez MF, Padilla-Fernández B, Flores-Fraile J, et al. "Impact of whole-cell bacterial immunoprophylaxis in the management of recurrent urinary tract infections in the frail elderly." Vaccine. 2021;39(42):6308–6314. doi:10.1016/j.vaccine.2021.08.093

16. Aziminia N, Hadjipavlou M, Philippou Y, et al. "Vaccines for the prevention of recurrent urinary tract infections: a systematic review." BJU Int. 2019;123(5):753–768. doi:10.1111/bju.14606

17. American College of Obstetricians and Gynecologists. "Urinary tract infections in pregnant individuals." Obstet Gynecol. 2023;142(2):435–445. doi:10.1097/AOG.0000000000005269

18. Nicolle LE, Gupta K, Bradley SF, et al. "Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America." Clin Infect Dis. 2019;68(10):e83–e110. doi:10.1093/cid/ciy1121

19. Apicella L, Vecchione N, Minelli G, et al. "Urinary tract infections in kidney transplant recipients: a narrative review." Transplant Proc. 2026. doi:10.1016/j.transproceed.2026.04.006

20. Milligan J, Goetz LL, Kennelly MJ. "A primary care provider's guide to management of neurogenic lower urinary tract dysfunction and urinary tract infection after spinal cord injury." Top Spinal Cord Inj Rehabil. 2020;26(2):108–115. doi:10.46292/sci2602-108

21. Ackerman AL, Bradley M, D'Anci KE, et al. "Updates to Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2025)." J Urol. 2025. doi:10.1097/JU.0000000000004723. Full guideline, statements 12–17.

22. Validus Pharmaceuticals LLC. HIPREX (methenamine hippurate tablets USP): US prescribing information. July 2021; DailyMed record revised February 2022. Prescribing information. Accessed September 11, 2026.

23. Lorenzo-Gómez MF, Foley S, Nickel JC, et al. Sublingual MV140 for prevention of recurrent urinary tract infections. NEJM Evid. 2022. doi:10.1056/EVIDoa2100018.

24. European Association of Urology. EAU Guidelines on Urological Infections. 2026. Full guideline.

25. AUA/SUFU. Adult neurogenic lower urinary tract dysfunction: treatment and follow-up. 2021. Statements 30–31 and 37–39. doi:10.1097/JU.0000000000002239.

26. Fisher H, Oluboyede Y, Chadwick T, et al. Continuous low-dose antibiotic prophylaxis for adults with repeated urinary tract infections (AnTIC): a randomised, open-label trial. Lancet Infect Dis. 2018;18:957–968. doi:10.1016/S1473-3099(18)30279-2.